- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03132506
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research Focused on Capture of Patient Reported Outcomes With Within PRAEGNANT Study Network
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Paperbacked pPRO data from up to a total of 100 patients from the cohort of PRAEGNANT are planned to be included in the Pepper I PRO study. Additionally 200 patients will be recruited in the web based ePRO cohort. The study duration per patient is at least 8 weeks. In cases of stable disease the study duration can be extended to up to 6 months with monthly PRO assessments, according to the attached visit matrix, taking approximately 20 minutes per visit.
The documentation at baseline should be performed during clinical routine with trained study personnel followed by remote self-reporting to minimize the patient effort. Pepper I will be conducted as sub-protocol of the PRAEGNANT trial.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Markus Wallwiener, MD
- Telefonnummer: 0049 6221 56-36956
- E-post: markus.wallwiener@med.uni-heidelberg.de
Studiesteder
-
-
-
Tübingen, Tyskland, 72076
- Rekruttering
- Department for Women's Health
-
Ta kontakt med:
- Andreas Hartkopf, Prof. Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients enrolled in PRAEGNANT
- Women aged ≥18 years
- Patients with the diagnosis metastasized breast cancer undergoing any form of systemic therapy
- Patients who are willing and able to sign the informed consent form
- Patients with therapy change
Exclusion Criteria:
- Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
- Patients who are not able to handle a tablet computer or are unable to write
- Patients who are not able to understand the nature and extent of the trial and the procedures require
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Annen
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
paper-based patient-reported-outcomes
|
Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
|
on web-based patient-reported-outcomes
|
Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
QLQ-C30 questionnaire for baseline
Tidsramme: 8 weeks
|
Overall patient completion rate in the paperbacked questionnaire and the web-tool, respectively
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
All other questionnaires for baseline and follow up time points.
Tidsramme: Baseline, 8 weeks
|
Overall patient completion rate in the paperbacked questionnaire and the web-tool, respectively,
|
Baseline, 8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
age
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
line of treatment
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
treatment
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
technical skills
|
8 weeks
|
Influence factors for the completion rates
Tidsramme: 8 weeks
|
patient's satisfaction
|
8 weeks
|
Adverse events-1
Tidsramme: 8 weeks
|
The date of clinical diagnosis of AE compared with the date of early AE onset
|
8 weeks
|
Adverse events-2
Tidsramme: 8 weeks
|
Consistency of AE documentation ePRO and clinician based
|
8 weeks
|
Patient satisfaction
Tidsramme: baseline, 4 weeks, 8 weeks
|
at baseline, after 4 weeks and after 8 weeks
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
EORTC QLQ C-30
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
BR23
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
NCCN distress thermometer,
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
EQ-VAS
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -1
Tidsramme: baseline, 4 weeks, 8 weeks
|
PHQ-9
|
baseline, 4 weeks, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements EQ-5D-5L measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements PROCTCAE Endocrine measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Health related quality of life (HRQL) assessements -2
Tidsramme: baseline, 8 weeks
|
The HRQL assessements PROCTCAE taxane measured at baseline and weekly (8 weeks)
|
baseline, 8 weeks
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- PEPPER
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft Metastatisk
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
I-Mab Biopharma Co. Ltd.Ikke lenger tilgjengeligSolid Tumor Metastatic Cancer Advanced Cancer
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
AmgenAktiv, ikke rekrutterendeKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, Forente stater, Canada, Belgia, Spania, Korea, Republikken, Nederland, Storbritannia, Australia, Danmark, Ungarn, Sverige, Taiwan, Hellas, Den russiske føderasjonen, Sveits, Frankrike, Italia, Japan, Polen, Brasil, Tyskland, ...
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på patient-reported-outcomes
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Har ikke rekruttert ennåType 2 diabetesForente stater
-
University Hospital, Basel, SwitzerlandFullførtSkade på fremre korsbånd (ACL)Sveits
-
Nova Scotia Health AuthorityRekruttering
-
Vanderbilt University Medical CenterNational Institute on Aging (NIA)FullførtPolyfarmasi | Geriatriske syndromer | OmsorgsovergangerForente stater
-
Shifa Tameer-e-Millat UniversityFullført
-
Denver Health and Hospital AuthorityMicrosoft Corporation; EMC ConsultingFullført
-
Ankara City Hospital BilkentFullførtSeksuell dysfunksjon | Vaginitt | Primært Sjögrens syndrom | Vaginitt CandidaTyrkia
-
Brigham and Women's HospitalGordon and Betty Moore FoundationFullførtPasienter på medisinsk intensivavdeling (MICU). | Onkologisk enhetspasienterForente stater
-
Zurich University of Applied SciencesKing's College London; Celgene Corporation; Kantonsspital Aarau; Klinik Hirslanden... og andre samarbeidspartnereAvsluttet